EP Patent

EP3421485A1 — Peptides for treatment and prevention of hyperglycaemia

Assigned to Vaxine Pty Ltd · Expires 2019-01-02 · 7y expired

What this patent protects

The present invention relates to peptides for the treatment or prevention of diabetes mellitus and associated disorders.

USPTO Abstract

The present invention relates to peptides for the treatment or prevention of diabetes mellitus and associated disorders.

Drugs covered by this patent

Subutex (BUPRENORPHINE) · Purdue Pharma Lp

Patent Metadata

Patent number: EP3421485A1
Jurisdiction: EP
Classification: —
Expires: 2019-01-02
Drug substance claim: No
Drug product claim: No
Assignee: Vaxine Pty Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.